Dornase alfa
- Generic Name
- Dornase alfa
- Brand Names
- Pulmozyme
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 143831-71-4
- Unique Ingredient Identifier
- 953A26OA1Y
- Background
Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphool...
- Indication
Used as adjunct therapy in the treatment of cystic fibrosis.
- Associated Conditions
- Cystic Fibrosis (CF)
- Associated Therapies
- -
Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)
- Conditions
- Interventions
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 36
- Registration Number
- NCT05880524
- Locations
- 🇩🇪
Institute for Stroke and Dementia Research, Ludwig Maximilian University Munich, University Hospital, Munich, Bavaria, Germany
Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- University of Melbourne
- Target Recruit Count
- 300
- Registration Number
- NCT05203224
- Locations
- 🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
Usefulness of DORNASE in COVID-19 on HFNO
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 10
- Registration Number
- NCT05139901
- Locations
- 🇸🇮
University Medical Centre Ljubljana, Ljubljana, Slovenia
Dornase Alpha for the Treatment of COVID-19
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Acibadem University
- Target Recruit Count
- 60
- Registration Number
- NCT04432987
- Locations
- 🇹🇷
Acıbadem Altunizade Hospital, Istanbul, Turkey
Pulmozyme to Improve COVID-19 ARDS Outcomes
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04402944
- Locations
- 🇺🇸
South Shore Hospital, Weymouth, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Dornase Alfa Administered to Patients With COVID-19 (DACOVID)
- Conditions
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Feinstein Institute for Medical Research
- Target Recruit Count
- 5
- Registration Number
- NCT04387786
- Locations
- 🇺🇸
Feinstein Insitute for Medical Research at Northwell Health, Manhasset, New York, United States
Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient
- Conditions
- Interventions
- First Posted Date
- 2014-06-20
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Duke University
- Target Recruit Count
- 39
- Registration Number
- NCT02168387
Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.
- Conditions
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- The Alfred
- Target Recruit Count
- 32
- Registration Number
- NCT01952470
- Locations
- 🇦🇺
The Alfred, Melbourne, Victoria, Australia
The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2011-11-23
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Sir Charles Gairdner Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT01478698
- Locations
- 🇦🇺
Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
Pulmozyme for Sjogren's Associated Cough
- First Posted Date
- 2011-05-20
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- UConn Health
- Registration Number
- NCT01357447
- Locations
- 🇺🇸
University of CT Health Center, Farmington, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.